| [1] |
Dent R, Trudeau M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence [J]. Clin Cancer Res, 2007, 13:4429-4434.
|
| [2] |
Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry [J]. Cancer, 2007, 109(9):1721-1728.
|
| [3] |
王炳高，袁新颜，邢志博，等，三阴性乳腺癌组织STAT3、AR、MMP-13表达与预后状况的关系研究[J]. 癌症进展，2016, 14(6): 594-596.
|
| [4] |
袁芃.2016年美国临床肿瘤学会年会报道：三阴性乳腺癌研究新进展[J/CD]．中华乳腺病杂志(电子版), 2016，10(5):264-268.
|
| [5] |
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple negative breast cancer subtypes and preclinical models for selection of targeted therapies [J]. J Clin Invest, 2011, 121(7):2750-2767.
|
| [6] |
叶青，江泽飞. 三阴性乳腺癌精准治疗的机遇[J]．中国肿瘤临床，2016, 43(24): 1074-1077.
|
| [7] |
Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer [J]. Nat Rev Drug Discov, 2009, 8(8):627-644.
|
| [8] |
Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signaling [J]. Nat Rev Mol Cell Biol, 2010, 11(11): 329-341.
|
| [9] |
Deng M, Wang J, Chen Y, et al. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway [J]. Anticancer Drugs, 2015, 26(4):422-427.
|
| [10] |
Bao GQ, Shen BY, Pan CP, et al. Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer [J]. Toxicol Lett, 2013, 222(1): 23-35.
|
| [11] |
李甜，周钱梅，张卫红．PI3K/Akt/mTOR信号通路在三阴性乳腺癌治疗中的研究进展[J]．中国肿瘤，2018，27(1):40-45.
|
| [12] |
Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials [J]. Pharmacol Ther, 2017, 175:91-106.
|
| [13] |
De P, Sun Y, Carlson JH, et al. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness [J]. Neoplasia, 2014, 16(1):43-72.
|
| [14] |
Speiser J, Foreman K, Drinka E, et al. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer [J]. Int J Surg Pathol, 2012, 20(2): 139-145.
|
| [15] |
王蕾，李燕辉，吴士茜，等．三阴乳腺癌中Notch1和Wnt1的表达及其临床意义[J]．实用心脑肺血管病杂志，2013，21(7):41-42.
|
| [16] |
Lafkas D, Rodilla V, Huyghe M, et al. Notch3 marks clonogenic mammary luminal progenitor cells in vivo[J]. J Cell Biol, 2013, 203(1): 47-56.
|
| [17] |
Naik S, MacFarlane M, Sarin A. Notch4 signaling confers susceptibility to TRAIL-induced apoptosis in breast cancer cells [J]. J Cell Biochem, 2015, 116(7): 1371-1380.
|
| [18] |
Nagamatsu I, Onishi H, Matsushita S, et al. NOTCH4 is a potential therapeutic target for triple-negative breast cancer [J]．Anticancer Res, 2014, 34(1):69-80.
|
| [19] |
Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions [J]. J Biol Chem, 1991, 266(12): 7313-7316.
|
| [20] |
Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily [J]．Trends Biochem Sci, 2002, 27(1): 19-26.
|
| [21] |
Warren MA, Shoemaker SF, Shealy DJ, et al. Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice [J]. Mol Cancer Ther, 2009, 8(9): 2655-2663.
|
| [22] |
Storci G, Sansone P, Mari S, et al. TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype [J]. J Cell Physiol, 2010, 225(3): 682-691.
|
| [23] |
Weichhaus M, Broom I, Bermano G. The molecular contribution of TNF-α in the link between obesity and breast cancer [J]. Oncol Rep, 2011, 25(2):477-483.
|
| [24] |
Kerstjens M, Driessen EM, Willekes M, et al. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations [J]. Oncotarget, 2016, 8 (9): 14 835-14 846.
|
| [25] |
刘兆芸，贺科文，宋兴国，等．自噬抑制剂可增强三阴性乳腺癌细胞系MDA-MB-468和MDA-MB-231对吉非替尼的敏感性[J]．中华肿瘤杂志，2016, 38(6): 417-424.
|
| [26] |
晏昱婧，胡小鹏，胡艺冰，等. 跨膜型TNF-α与NF-κB在三阴性乳腺癌中的表达及其意义[J]. 现代生物医学进展，2014, 14(15):2819-2822.
|
| [27] |
Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics [J]. Oncogene, 2010, 29(5):625-634.
|
| [28] |
Zhang Y, Dai J, McNamara KM, et al. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases [J]. BMC Cancer, 2015, 15:699.
|
| [29] |
Regan Anderson TM, Ma SH, Raj GV, et al. Breast tumor kinase (Brk/PTK6) is induced by HIF, glucocorticoid receptor, and PELP1-mediated stress signaling in triple-negative breast cancer [J]. Cancer Res, 2016, 76(6):1653-1663.
|
| [30] |
Gucalp A, Traina TA. Targeting the androgen receptor in triple-negative breast cancer [J]. Curr Probl Cancer, 2016, 40(2-4):141-150.
|
| [31] |
杨满，韦伟．雄激素受体在乳腺癌治疗中的研究进展[J/CD]．中华乳腺病杂志(电子版)，2017，11(5):296-299.
|
| [32] |
Pietri E, Conteduca V, Andreis D, et al. Androgen receptor signaling pathways as a target for breast cancer treatment [J]. Endocr Relat Cancer, 2016, 23(10): R485-R498.
|
| [33] |
Gucalp A, Tolaney S, Isakoff SJ, et al. Phase Ⅱ trial of bicalutamide in patients with androgen receptor-positive estrogen receptor-negative metastatic breast cancer [J]. Clin Cancer Res, 2013, 19(19): 5505-5512.
|
| [34] |
Arce-salinas C, Riesco-maritne MC, Hanna W, et al. Complete response of metastatic androgen receptor positive breast cancer to bicalutamide: case report and review of the literature [J]. J Clin Oncol, 2016, 34(4): e21-e24.
|